Disease Progression and Pharmacological Intervention in a Nutrient-Deficient Rat Model of Nonalcoholic Steatohepatitis

Characterization of the properties of a selective, orally bioavailable autotaxin inhibitor in preclinical models of advanced stages of liver fibrosis

(2018) Manuel Baader et al.   BRITISH JOURNAL OF PHARMACOLOGY

Lipotoxicity and the gut-liver axis in NASH pathogenesis

(2018) Fabio Marra et al.   JOURNAL OF HEPATOLOGY

Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why liver biopsy is essential

(2018) Pierre Bedossa   LIVER INTERNATIONAL

Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis

(2018) Kirstine S Tølbøl et al.   WORLD JOURNAL OF GASTROENTEROLOGY

INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis

(2018) Jonathan D Roth et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet

(2017) Ayae Ikawa-Yoshida et al.   INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY

Pathology of non-alcoholic fatty liver disease

(2017) Pierre Bedossa   LIVER INTERNATIONAL

Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models

(2017) Mukul R. Jain et al.   LIVER INTERNATIONAL

The epidemiology of non-alcoholic fatty liver disease

(2017) Stefano Bellentani   LIVER INTERNATIONAL

Induction of Steatohepatitis (NASH) with Insulin Resistance in Wild-type B6 Mice by a Western-type Diet Containing Soybean Oil and Cholesterol

(2017) Janin Henkel et al.   MOLECULAR MEDICINE

Targeting nuclear receptors for the treatment of fatty liver disease

(2017) Naoki Tanaka et al.   PHARMACOLOGY & THERAPEUTICS

Novel PPARα agonist MHY553 alleviates hepatic steatosis by increasing fatty acid oxidation and decreasing inflammation during aging

(2017) Seong Min Kim et al.   Oncotarget

Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease

(2017) Wenjing Luo et al.   Scientific Reports

Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice

(2017) Hani Jouihan et al.   Molecular Metabolism

Non-alcoholic fatty liver disease in 2016

(2016) S.A. Townsend et al.   BRITISH MEDICAL BULLETIN

Emerging therapeutic targets for the treatment of hepatic fibrosis

(2016) Paolo Fagone et al.   DRUG DISCOVERY TODAY

Obeticholic Acid: First Global Approval

(2016) A. Markham et al.   DRUGS

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

(2016) Vlad Ratziu et al.   GASTROENTEROLOGY

Non-alcoholic steatohepatitis-associated hepatic fibrosis and hepatocellular carcinoma in a combined mouse model of genetic modification and dietary challenge

(2016) Yuichiro Amano et al.   HEPATOLOGY RESEARCH

A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer

(2016) Amon Asgharpour et al.   JOURNAL OF HEPATOLOGY

Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies

(2016) Giovanni Musso et al.   NATURE REVIEWS DRUG DISCOVERY

Obeticholic acid improves adipose morphometry and inflammation and reduces steatosis in dietary but not metabolic obesity in mice

(2016) Fahrettin Haczeyni et al.   Obesity

The Role of Cholesterol in the Pathogenesis of NASH

(2016) George N. Ioannou   TRENDS IN ENDOCRINOLOGY AND METABOLISM

Kupffer Cells Undergo Fundamental Changes during the Development of Experimental NASH and Are Critical in Initiating Liver Damage and Inflammation

(2016) D. T. Reid et al.   PLoS One

The impact of PPARα activation on whole genome gene expression in human precision cut liver slices

(2015) Aafke W.F. Janssen et al.   BMC GENOMICS

Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats

(2015) Yuka Hayashizaki-Someya et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

(2015) Paul Angulo et al.   GASTROENTEROLOGY

Bile acids: emerging role in management of liver diseases

(2015) Amon Asgharpour et al.   Hepatology International

Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease

(2015) Michal Pawlak et al.   JOURNAL OF HEPATOLOGY

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

(2015) Brent A Neuschwander-Tetri et al.   LANCET

Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease

(2015) Hyun Jung Lee   WORLD JOURNAL OF GASTROENTEROLOGY

Nonalcoholic fatty liver disease

(2015) Elizabeth M. Brunt et al.   Nature Reviews Disease Primers

NLRP3 inflammasome activation is required for fibrosis development in NAFLD

(2014) Alexander Wree et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Overactivation of Intestinal SREBP2 in Mice Increases Serum Cholesterol

(2014) Ke Ma et al.   PLoS One

HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH

(2014) Samuele De Minicis et al.   PLoS One

Establishment of a General NAFLD Scoring System for Rodent Models and Comparison to Human Liver Pathology

(2014) Wen Liang et al.   PLoS One

Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment

(2013) Jason R. Clapper et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

(2013) Bart Staels et al.   HEPATOLOGY

The portal inflammatory infiltrate and ductular reaction in human nonalcoholic fatty liver disease

(2013) Victoria L. Gadd et al.   HEPATOLOGY

Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model

(2013) Yosuke Aihara et al.   HEPATOLOGY RESEARCH

An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis

(2013) Masahiko Matsumoto et al.   INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY

Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis

(2013) Hitoshi Yoshiji et al.   JOURNAL OF GASTROENTEROLOGY

NAFLD, NASH and liver cancer

(2013) Gregory A. Michelotti et al.   Nature Reviews Gastroenterology & Hepatology

Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice

(2012) James L. Trevaskis et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2

(2012) Kouichi Miura et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Liver Transplantation for Nonalcoholic Steatohepatitis

(2012) Vatche G. Agopian et al.   ANNALS OF SURGERY

Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis

(2012) Yosui Tamaki et al.   JOURNAL OF GASTROENTEROLOGY

Roles of PPARs in NAFLD: Potential therapeutic targets

(2011) Anne Tailleux et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS

Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and toll-like receptor activation

(2011) Christian L. Roth et al.   HEPATOLOGY

Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist’s perspective

(2011) Carolin Lackner   Expert Review of Gastroenterology & Hepatology

Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation

(2010) Massimo Collino et al.   BRITISH JOURNAL OF PHARMACOLOGY

Toll-Like Receptor 9 Promotes Steatohepatitis by Induction of Interleukin-1β in Mice

(2010) Kouichi Miura et al.   GASTROENTEROLOGY

Kupffer cells in non-alcoholic fatty liver disease: The emerging view

(2009) György Baffy   JOURNAL OF HEPATOLOGY

Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis

(2009) Songwen Zhang et al.   JOURNAL OF HEPATOLOGY

Immunotherapy for nonalcoholic steatohepatitis using themultiple cytokine production modulator Y-40138

(2009) Tatsuhiro Tsujimoto et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease

(2008) K Fujita et al.   GUT

Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet

(2008) Mary E. Rinella et al.   JOURNAL OF LIPID RESEARCH

Innate immune reactivity of the liver in rats fed a cholinedeficient L-amino-acid-defined diet

(2008) Hideto Kawaratani et al.   WORLD JOURNAL OF GASTROENTEROLOGY

PPARα: Mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators

(2007) Frank J. Gonzalez et al.   TOXICOLOGY